Shares straight up and straight down on fresh Oslo Børs – OBI Online

Oslo Stock Exchange continued the good mood from morning through the day Friday.

The main index ended at 623.82, up 1.33 percent.

Shares and equity certificates traded for approximately 4.76 billion.

The main index rose 7.69 percent last month, while it is up 8.29 percent so far this year.

– Everything I see is euphoria
trends occurred in the wake of the rally on Wall Street yesterday and in Asia bourses earlier today.

The rally linked to statements from Governor Mario Draghi in the aftermath that the European Central Bank (ECB) kept its key rate unchanged at this week’s meeting.

Draghi let yesterday did not hide that he is willing to take all the funds used to accelerate growth in the eurozone.

– All I see this morning’s euphoria, after Mario Draghi and his elves in ECB in practice confirmed that they will come with an early Christmas present to the European economy on December 3. Draghi gift is a global gift, writes IG strategist Evan Lucas according to CNBC in a note early Friday.

– The expectation now is that Draghi will announce a prolonged (perhaps even non-defined) of bond purchases program, probably far in 2017, he adds.

Europe
European bourses draws Wednesday afternoon wide upward. DAX in Frankfurt rising 2.89 percent, the FTSE 100 in London is up 1.13 percent, while the CAC 40 in Paris rising 2.52 percent.

It happens partly as a result of interest rate cuts in China.

China cut the country’s one-year deposit and lending rates by 0.25 percentage points to 4.35 per cent with effect from 24 October.

In addition, cuts China all banks’ reserve requirement ratio by 0.5 percentage points . For some institutions cut the rate by a further 0.5 percentage points.

Oil prices turned down
Oil prices have during the day turned from plus one percent to minus one percent.

Brent December oil falls by close of trading with 1.00 percent to $ 47.60 in today’s trading, after the front contract was traded around $ 48.30 a barrel at closing in Oslo yesterday.

In the oil sector rose Statoil 0.49 percent to 143.70 kroner, while DNO ended flat at 8.90 million of received KRG payments.

Cool Gjensidige rally
Gjensidige dominated among the heavyweights Friday and rose 12.28 percent to 128 kroner at high volume.

The reason today’s interim report, which the company could report a record profit of disaster insurance. The bottom line dwindled dog in 40 percent.

Another figure presents, TGS, perform well in time of crisis, and delivered better than expected in Q3.

The stock was up 4.52 percent to 166.50 kroner.

Impairments burdened PGS accounts, but the market still sent the stock up 4.28 percent to 36.08 kroner.

Among other positive heavyweights we highlight Telenor plus 2.32 percent to 171.70 kroner, while Subsea 7, Marine Harvest, Orkla and Schibsted A gained 1.3 percent.

Dolphin-ras
Fred. Olsen Energy plunged over 13 percent yesterday after notification billion claim from the Hyundai shipyard.

The stock was currently up 0.51 percent to 43.22 kroner.

Dolphin Group was punished with a fall in violent 40.74 percent to 32 cents after notice of termination for Sanco Swift and Sanco Sword.

Norwegian fell 3.80 percent to 308.50 kroner in the wake of yesterday’s quarterly and Dreamliner purchase . The company told today that the agreement with the Swedish state is extended by one year.

DNB continued downturn after figures yesterday. Citi and Bank of America have both reacted by downgrading the stock, which fell 0.54 percent to 109.50 kroner – the stock was number two on the sales list.

Bergen Group
Bergen Group ASA is about to finalize a strategic and operational clearing process that will contribute to future growth and continued profitability of the Group’s remaining operations, goes forward to a press release Friday.

– We’ve been through some very demanding, but wholly necessary changes that have both including divestments and bankruptcy in subsidiaries. This has also happened in a period of decline in activity in large parts of the offshore-related industry, which caused us some extra challenges, says CEO Hans Petter Eikeland.

– Now we see the outlines of a future that makes it possible to think growth based on profitable conditions, he said.

The stock rose today most of all, with nothing less than 68.83 percent to 1.30 million. Turnover was however not all the world with just over 1.2 million.

Winners and Losers
Relatively speaking comes Tide almost said Bergen Group on the winners, gaining at 14.04 percent to 20.30 kroner on thin volume.

Oslo Axess-listed Nordic Mining drew up 9.84 percent to 67 cents, while PCI Biotec rose 11.75 percent to 5.99 million .

At the other end lay GC Rieber Shipping closest mentioned Dolphin Group – down 15.25 percent to 11.95 kroner.

Zoncolan fell 13.46 percent to 45 cents, Supply shipping company DOF went back 11.67 percent to 5.30 million, while Reach Subsea pulled down 13.18 percent to 1.91 million.

RCCL Century
3 . quarter 2015 received Royal Caribbean Cruise Lines (RCCL) an adjusted profit of $ 2.84 per share.

According to TDN Finans had the lead ahead guided a profit of around $ 2.70 per share.

RCCL takes a provision of Pullmantur on $ 399.3 million

Furthermore, it has been known that lead initiate a share buyback program where RCCL will buy own shares for $ 500 million.

On the Oslo Stock Exchange stock rose today 6.13 percent to 822 kroner. Today’s highest price was at 829.50 million, which is all-time high intraday.

Ferraris stock exchange debut upshift Wall Street – Manager

Publisert 21.10.15 15:19 Sist oppdatert 21.10.15 15:52

Promotion med annonselenker

GM opp på solide tall. Knallstart for børsdebutanten Ferrari.

Pilene pekte mot en positiv start på amerikanske børser onsdag etter en ny runde selskapsresultater, mens investorene også retter blikket mot en av årets største børsnoteringer.

I tidlig handel er Dow Jones-indeksen opp 0,28 prosent, S&P 500 stiger 0,21 prosent og Nasdaq er opp 0,31 prosent.

Bilprodusenten General Motors stiger over fire prosent etter å ha rapportert et nettoresultat på 1,4 milliarder dollar for tredje kvartal, på linje med tredje kvartal i fjor. Det justerte resultatet på 1,50 dollar per aksje overgår imidlertid forventningene på 1,12 dollar i en FactSet-undersøkelse.

Tar Ferrari på børs
Onsdag er også første handelsdag for luksusbilprodusenten Ferrari på New York-børsen, som naturlig nok har fått tickeren «RACE».

Dagen starter med full gass for aksjen, som sendes opp over 13 prosent.

- Begeistring over Ferraris børsnotering hjelper amerikanske aksjer mot en positiv åpning, bemerker CMC Markets-analytiker Jasper Lawler i et notat, ifølge Marketwatch.

I forkant av børsnoteringen har Ferrari hentet 893 millioner dollar i et aksjesalg, ifølge Financial Times. Kursen i tilbudet på 52 dollar verdsetter bilprodusenten til 9,8 milliarder dollar, tilsvarende nær 80 milliarder dollar.

Prisingen er også i den øvre enden av det forespeilede intervallet, noe som indikerer sterk interesse fra investorene.

Ferrari spinnes ut fra Fiat Chrysler, som selger en eierandel på rundt 10 prosent. Den resterende eierandelen på 80 prosent planlegger Fiat å dele ut til egne investorer neste år, ifølge Bloomberg.

Samtidig vil grunnleggeren Enzo Ferrari sin sønn Piero Ferrari beholde et eierskap på 10 prosent.

I fjor produserte Ferrari 7.255 biler og hadde en omsetning på 2,8 milliarder euro.

Børsnoteringen er den fjerde største hittil i 2015, et år som har vært det svakeste for amerikanske nye børsnoteringer siden 2010.

Resultatskred
I tillegg leveres det en rekke selskapsresultater for tredje kvartal. Både General Motors og Coca-Cola er blant de 32 S&P 500-selskapene som legger frem tall i dag.

Coca-Cola faller derimot 1 prosent etter at nettoresultatet falt til 1,45 milliarder dollar i tredje kvartal, fra 2,11 milliarder dollar i tilsvarende kvartal i fjor.

Lik NA24 her og få flere ferske økonominyheter!

Health Topper fear revolutionary cancer medicine will crack economy – TV 2

As TV 2 previously told a new type of immunotherapy with so-called PD1 inhibitors, which help the body’s own immune system to fight cancer, has shown very promising results.

Patients who are affected by several types of cancer have been given extended life and improved quality of life. In addition, PD1 inhibitors be appropriate to use against a variety of other cancers.

The problem is that the drug is very expensive.

Can cost billions

With a price of 1.1 million per patient per year, the new treatment may cost up to three billion for health regions, says technical director Bård-Christian scheme in Helse Vest in a memo to his colleagues, writes Bergens Tidende .

Some 1,500 lung cancer patients is appropriate for getting PD1-drug. The price for the current medications for these patients is approximately 10,000 per year.

– This whole medicine group is very exciting. And I would have thought that we would see a strong development in this group ahead, both in effect and that it goes down in price , says Lars Vorland, Director of Health North, to TV 2.

But he is also very concerned about the staggering sums on drugs.

A preliminary “no”

Norwegian lung cancer association believes treatment should be used immediately, while Decision Forum for new methods – in which the directors of the four health regions sitting – have said a provisional no.

The forum will examine each of the major costs will pay off economically before they say yes. Health Bent Høie refuses pharmaceutical companies to dictate the price.

Medicines Agency has not considered the matter yet.

admits that approval takes time

And while Norwegian patients have to wait, you Danish people with cancer already use the expensive immunotherapy-medicines.

– Is it too long before you get an approval in Norway?

– In Denmark also problems that the cost of these medications are too great. We discuss how we can use all these drugs, for the price is very high. We want these medications, but it must be at a price that is acceptable, says Lars Vorland.

– But do you use for a long time?

– We has enough spent any time at any of the drugs. I think time will go down, but it takes time to make technology assessment, says Vorland .

Requires health minister on the field

The forum will ask the Ministry of Health involved in the question of how the galloping costs shall be dealt with.

Health Minister Bent Høie (H) says the hospitals’ budgets have increased in recent years to meet increased costs. But he is clear that pharmaceutical companies are not allowed to dictate prices.

(TV 2 / NTB)

Ferrari with top speed of exchange – Manager

Publisert 21.10.15 22:47 Sist oppdatert 21.10.15 22:47

Promotion med annonselenker

Wall Street-debuten gikk meget bra.

NEW YORK (Nettavisen): Når Ferrari onsdag ble introdusert på New York-børsen, fikk aksjen selvfølgelig registreringsnummeret «RACE». Den fikk også god fart på seg.

Den åpnet med en kurs på 52 dollar, men gikk raskt opp over 13 prosent. På sitt meste var den oppe i 60,07 dollar.

Ferrari-aksjen endte sin første børsdag med en kurs på 55 dollar blankt. Det er en oppgang på 5,77 prosent.

- Begeistring over Ferraris børsnotering hjelper amerikanske aksjer mot en positiv åpning, bemerker CMC Markets-analytiker Jasper Lawler i et notat, ifølge Marketwatch.

I forkant av børsnoteringen hentet Ferrari 893 millioner dollar i et aksjesalg, ifølge Financial Times. Kursen i tilbudet på 52 dollar verdsetter bilprodusenten til 9,8 milliarder dollar, tilsvarende nær 80 milliarder dollar.

Piero Ferrari, grunnlegger Enzo Ferraris sønn, vil beholde et eierskap på 10 prosent. Ferrari omsatte for 2,8 milliarder euro i fjor, ifølge Bloomberg.

Ellers var det lite jubel på Wall Street onsdag. Dow Jones falt 0,28 prosent til 17.169 poeng, Nasdaq falt 40,85 poeng til 4840 og Standard & Poor 500 gikk ned 11,83 poeng til 2019.

Lik NA24 her og få flere ferske økonominyheter!

Health Topper fear we can not afford the new super medicine against cancer – TV 2

As TV 2 previously told a new type of immunotherapy with so-called PD1 inhibitors, which help the body’s own immune system to fight cancer, has shown very promising results.

Patients who are affected by several types of cancer have been given extended life and improved quality of life. In addition, PD1 inhibitors be appropriate to use against a variety of other cancers.

The problem is that the drug is very expensive.

Can cost billions

With a price of 1.1 million per patient per year, the new treatment may cost up to three billion for health regions, says technical director Bård-Christian scheme in Helse Vest in a memo to his colleagues, writes Bergens Tidende .

Some 1,500 lung cancer patients is appropriate for getting PD1-drug. The price for the current medications for these patients is approximately 10,000 per year.

– This whole medicine group is very exciting. And I would have thought that we would see a strong development in this group ahead, both in effect and that it goes down in price , says Lars Vorland, Director of Health North, to TV 2.

But he is also very concerned about the staggering sums on drugs.

A preliminary “no”

Norwegian lung cancer association believes treatment should be used immediately, while Decision Forum for new methods – in which the directors of the four health regions sitting – have said a provisional no.

The forum will examine each of the major costs will pay off economically before they say yes. Health Bent Høie refuses pharmaceutical companies to dictate the price.

Medicines Agency has not considered the matter yet.

admits that approval takes time

And while Norwegian patients have to wait, you Danish people with cancer already use the expensive immunotherapy-medicines.

– Is it too long before you get an approval in Norway?

– In Denmark also problems that the cost of these medications are too great. We discuss how we can use all these drugs, for the price is very high. We want these medications, but it must be at a price that is acceptable, says Lars Vorland.

– But do you use for a long time?

– We has enough spent any time at any of the drugs. I think time will go down, but it takes time to make technology assessment, says Vorland .

Requires health minister on the field

The forum will ask the Ministry of Health involved in the question of how the galloping costs shall be dealt with.

Health Minister Bent Høie (H) says the hospitals’ budgets have increased in recent years to meet increased costs. But he is clear that pharmaceutical companies are not allowed to dictate prices.

(TV 2 / NTB)

Norwegian big banks wary of Chinese growth figures – Manager

Seniorøkonom og tidligere sjeføkonom i Handelsbanken, Knut Anton Mork, har  ikke noe klart grunnlag for å hevde at kinesiske veksttall er sminket, men han har lenge hatt en mistanke om at kinesiske data er en smule glattet, enten veksten er høy eller lav. (Handelsbanken)

- What is good assessment work in your nursery? – Education Association

publisert 20.10.2015

−Vi har laget et debattnotat som kan brukes som et verktøy til å drøfte hva som er godt vurderingsarbeid i din barnehage, sier Steffen Handal.

− Vi ser en økende tendens til at styrere pålegges å ta i bruk ulike verktøy og metoder i barnehagen. Dette gjelder særlig verktøy og metoder for vurdering og dokumentasjon. I noen tilfeller oppleves ikke disse som det beste for barnehagen og barna. Vi ønsker derfor å støtte styrere og pedagogiske ledere i å ta gode valg. Valgene skal være til det enkelte barns beste, og i tråd med samfunnsmandatet vårt, sier Steffen Handal. 

Vil skape bevissthet
Utdanningsforbundet har laget debattnotatet for å bidra til bevissthet om hva som er godt vurderingsarbeid. 

Her finner du notatet:

Debattnotat om vurderingsarbeid i barnehagen

I notatet finner du rammeplanens bestemmelser om vurdering, hva som er Utdanningsforbundets syn, og sist, men ikke minst, lister vi opp en rekke spørsmål om vurdering til debatt og refleksjon. 

− Vi håper notatet kan være til hjelp for styrere og pedagogiske ledere i arbeidet med å skape bevissthet om vurderingsarbeidet i egen barnehage. Vi ønsker også å bidra til dialog med andre styrere og samarbeidspartnere om hva som er god vurdering i barnehagen. Gjennom lærerprofesjonens etiske plattform forplikter barnehagelærerne seg på å være faglig funderte og etiske reflekterte i arbeidet med vurdering, fortsetter Handal.

Utdanningsforbundet mener:

• Barnehagen ved styrer skal ha hovedansvaret for barnehagens pedagogiske arbeid herunder valg av metoder og verktøy. 
• Eier må sørge for gode rammer for å sikre dette arbeidet. 
• Innkjøp av verktøy og pedagogisk materiell må diskuteres med styrerne og være et tilbud barnehagene kan benytte ved behov. 
• Eier bør også legge til rette for samarbeid mellom barnehagene og helsestasjoner, ppt og barnevern for å sikre oppfølging av barns utvikling og trivsel. 

Barnehageloven
Vårt utgangspunkt er dagens Rammeplan for barnehagens innhold og oppgaver og de føringer den gir for dokumentasjons- og vurderingsarbeidet i barnehagen. Regjeringen sendte vinteren 2014 ut forslag om å flytte hjemmelen for barnehagens dokumentasjons- og vurderingsarbeid fra rammeplanen til loven. En av begrunnelsene for forslaget er å sikre tidlig innsats og systematisk tilbud til alle barn i tråd med §§ 1 og 2 i loven. 

− Vi ønsker selvfølgelig å bidra konstruktivt for å sikre barn et tilbud i tråd med dagens lovtekst. Regjeringen har foreslått at barnehageeier skal ha rett til å velge system, verktøy og observasjonsmetoder. Det er vi uenig i. Det er styreren som kan, og skal ha, et hovedansvar for det pedagogiske arbeidet i barnehagen. Sammen med de pedagogiske lederne er det styrerne som bør ha et særlig ansvar for hvordan barnehagen planlegger, vurderer og dokumentetere arbeidet, mener nestlederen.

Det er de som står i det direkte møtet med barna, og som derfor vil treffe de avgjørelsene som er til barnets beste.  Han mener at profesjonen må kunne forklare, forsvare og begrunn hvordan vi sikrer alle barna et tilrettelagt godt tilbud og hvordan vi best sikrer at barn som trenger særskilt hjelp og støtte fanges opp. Debattnotatet er et bidrag til dette arbeidet.